Med-IQ Logo
Get CME/CE
Newborn Screening for Lysosomal Diseases: Recent Progress and Unanswered Questions
Symposium Symposium

Newborn Screening for Lysosomal Diseases: Recent Progress and Unanswered Questions


Time to Complete:
1.5 hours
Released:
2/13/17
Expires:
4/13/17

Maximum Credits:

1.5 AMA PRA Category 1 Credit(s)

Symposium Symposium
Time to Complete:
1.5 hours

Released:
2/13/17

Expires:
4/13/17

Maximum Credits:
1.5 AMA PRA Category 1 Credit(s)
Share on:
Symposium Symposium

Share on:


Time to Complete:
1.5 hours
Released:
2/13/17
Expires:
4/13/17


Maximum Credits:
1.5 AMA PRA Category 1 Credit(s)


Overview: Join us at this 1.5- hour, CME-certified satellite symposium with dinner, offered on February 13th in San Diego, with nationally renowned expert pediatricians Barbara K. Burton, MD, Priya S. Kishnani, MD, and Melissa Wasserstein, MD. Together, these experts in lysosomal diseases (LDs) and newborn screening (NBS) will review the updated Recommended Uniform Screening Panel and discuss the current landscape of NBS for LDs in the United States. The faculty panel will also focus on current challenges with NBS and share interesting responses from a practice questionnaire that will be completed by participants.

Faculty

Barbara K. Burton, MD

Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Division of Genetics, Birth Defects & Metabolism

Ann & Robert H. Lurie Children’s Hospital

Chicago, IL

Priya S. Kishnani, MD

C.L. and Su Chen Professor of Pediatrics

Medical Director, YT and Alice Chen Pediatrics Genetics and Genomic Center

Division Chief, Medical Genetics

Duke University Medical Center

Durham, NC

Melissa Wasserstein, MD

Associate Professor of Pediatrics and Genetics

The University Hospital for Albert Einstein College of Medicine

Chief, Division of Pediatric Genetic Medicine

The Children's Hospital at Montefiore

Bronx, NY


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Barbara K. Burton, MD
Consulting fees/advisory boards: Alexion, ArmaGen, BioMarin, REGENXBIO Inc., Sanofi Genzyme
Fees received for promotional/non-CME activities: Alexion, Shire
Contracted research: Alexion, ArmaGen, BioMarin, Shire, Ultragenyx Pharmaceutical
 
Priya S. Kishnani, MD
Consulting fees/advisory boards: Amicus Therapeutics, Inc., Sanofi Genzyme
Ownership interest (stocks/stock options – excluding mutual funds): Baebies
 
Melissa Wasserstein, MD
Consulting fees/advisory boards: Sanofi Genzyme
Contracted research: Sanofi Genzyme

The peer reviewers and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Sanofi Genzyme.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.
Play Video
The trifecta of healthcare improvement: value-based care, quality improvement, and technology.

See how Med-IQ is helping to enhance patient outcomes in these short videos.

Scott Weber, CEO Med-IQ

From Volume to Value-Based Care: The Role of the CME Enterprise

Scott Weber, CEO,
Med-IQ

Allison Gardner, PhD, VP Educational Strategy and Content, Med-IQ

The Value of Quality Improvement and Education to Advance Healthcare

Allison Gardner, PhD,
VP Educational Strategy and Content,
Med-IQ

Dr. Glenn Treisman,
Department of Psychiatry, Johns Hopkins Medical Institute

The Pros and Cons of Technology on the Practice of Medicine

Dr. Glenn Treisman,
Department of Psychiatry,
Johns Hopkins Medical Institute


Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.